| Today’s Big NewsMar 7, 2025 |
|
Tuesday, March 11, 2025 | 11am ET / 8am PT In the world of clinical trials, where precision and compliance are critical, the role of technology is more important than ever. Join us to learn how to harness the latest innovations for driving efficiencies and more streamlined experiences for patients. Register now to take a deep dive into the most pressing challenges in clinical trials today!
|
|
| By Kevin Dunleavy A Texas court has rejected a request by compounders to extend their ability to manufacture knockoff versions of Eli Lilly's tirzepatide while a lawsuit plays out. |
|
|
|
By Gabrielle Masson Nasdaq plans to roll out 24-hour trading for U.S. companies in a move designed to modernize the market. |
By Conor Hale The FTC said merging Surmodics with Biocoat, where GTCR has a majority stake, would result in one company with over 50% of the hydrophilic coating market. |
By Gabrielle Masson In defiance of federal orders, the National Institutes of Health is still terminating grants to researchers across the country, The Boston Globe reports. |
By Andrea Park Otsuka America Pharmaceutical is continuing its work to provide support to and advocate for family caregivers. |
By Angus Liu AstraZeneca is preparing to talk to the FDA about a potential new use of its immunotherapy Imfinzi after a pivotal study in early-stage stomach cancer met its main goal. |
By Nick Paul Taylor Amgen and CytomX Therapeutics have kicked a phase 1 T-cell engager to the curb, axing the asset after assessing the clinical data and their pipeline priorities. |
By Fraiser Kansteiner While Novo Nordisk has been operating in rare disease for some 45 years, the field has often taken a back seat to the Danish drugmaker’s bread-and-butter business developing treatments for diabetes and other common chronic diseases. Still, Novo is steadfast in its goal to eventually become a leader in the space, the company’s EVP of rare disease, Ludovic Helfgott, said in an interview. |
By Darren Incorvaia,Zoey Becker Sage Chief Medical Officer Laura Gault, M.D., Ph.D., is stepping down to pursue a new opportunity effective March 21, the latest change for a company that has had a recent string of clinical failures. |
By Conor Hale Boston Scientific led a $175 million funding round for 4C Medical, which is taking a different approach to mitral regurgitation. |
By Nick Paul Taylor Vertex is putting marketing might behind its push into kidney conditions, profiling a patient’s experience of being diagnosed with a genetic disease as part of its commemoration of kidney disease awareness month. |
By Darren Incorvaia The National Institutes of Health unveiled a plan on March 6 to move the peer review of grant applications, cooperative agreements and research and development contracts to a central location at the agency’s Center for Scientific Review (CSR). |
By Fraiser Kansteiner In 2024, Bayer chief Bill Anderson’s total compensation fell about 21% to 8.84 million euros ($9.6 million). The decline shouldn’t come as a total shock, given that 3.8 million euros of Anderson’s 2023 pay package came from a one-time "indemnity payment" he received after leaving Roche. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we dig into several of the biggest private funding rounds in biotech last year and discuss the shifting VC landscape. |
|
|---|
|
|
|
Wednesday, April 9, 2025 | 10am ET / 7am PTLearn the key steps for successfully entering Japan’s pharmaceutical market. This webinar covers regulatory requirements, compliance strategies, supply chain best practices, and common challenges. Gain expert insights to navigate this high-potential market with confidence. Don’t miss out—register now to secure your spot!
|
|
| WhitepaperRead about four trends that will shape the innovations, therapies, & market landscape in oncology during 2025 & beyond. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperDiscover how to revolutionize your vaccine trials with Avacare's latest white paper. Gain exclusive access to innovative, data-driven recruitment strategies that ensure diverse, efficient, and high-quality vaccine trials. Sponsored by: Avacare Clinical Research Network |
| WhitepaperDevelop your CAR molecule faster Sponsored by: Cell Signaling Technology |
| |
|
